TapImmune, Inc. (TPIV)

Take a look at some of our previously featured companies

TapImmune, Inc. (TPIV)

Postby QualityStocks » Fri Nov 20, 2009 10:40 am

TapImmune, Inc. is a biotechnology company focused on developing innovative therapeutics and vaccines in the areas of oncology and infectious disease. The company’s lead product, the TAP vaccine, is a key component of a mechanism that moves characteristic markers called antigens to the surfaces of cells. Without TAP, there is a large reduction in presentation of cancer markers, making it impossible for the immune system to spot rogue cells and cancerous cells, allowing them to grow undetected.

The company’s vaccine has demonstrated its effectiveness in restoring TAP which in-turn restores and augments the characteristic marker (antigen) and subsequent recognition and killing of cancer cells by the immune system. The TAP molecule also works to enhance targeted vaccines against infectious diseases. For example, including TAP in the studied Smallpox Vaccine showed potency was increased by 100-1,000 times.

TapImmune's technologies have broad applications in developing therapeutic and preventative vaccines. The company’s technologies have been featured on ABC News BusinessNow, B-TV, in BusinessWeek, Popular Mechanics and local news papers as well as many respected medical journals including the Journal of Immunology, Nature (Biotechnology), International Journal of Cancer, Cancer Research and PLoS Pathogens, among others.

Management believes that its cancer vaccine strategy is a unique therapeutic approach that addresses the problem of poor immune responses to cancer. Since restoring the TAP protein directs the body’s immune system to specifically target cancerous cells without damaging healthy tissue, this therapy potentially has a strong competitive advantage over other cancer therapies.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Video Charts http://Videocharts.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please see our Profile for Disclaimers
QualityStocks
Site Admin
 
Posts: 8965
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Postby mwest » Mon Nov 23, 2009 6:28 pm

this company is off to a great start with a much needed product
I am not a registered investment advisor and receive payment from DreamTeamGroup for research (view disclaimers: http://dreamteamgroup.com/disclaimer.html).
mwest
 
Posts: 10383
Joined: Thu Apr 09, 2009 3:09 pm

Postby QualityStocks » Tue Nov 24, 2009 10:49 am

TapImmune, Inc. (TPIV.OB) Among the Winners in the Booming Vaccine Business

Recent headlines swirling around the swine flu have centered the focus of both the public and investors on vaccines and the vaccine industry. The vaccine marketplace is expected to show big gains through 2012 as it emerges as one of the most lucrative sectors of the global pharmaceutical industry. This bodes well for innovative companies such as TapImmune Inc. (OTCBB: TPIV).

TapImmune is a biotechnology company specializing in the development of cell-based vaccines and immunotherapeutics in the areas of oncology and infectious disease. The company’s vaccine technology is based on modulating the activity of the antigen processing machinery to increase effective presentation of antigens to the immune system. Transporters associated with antigen processing (TAP) play a major role in the antigen processing pathway.

One of the most lucrative areas for vaccine makers is vaccines which may treat various forms of cancer. The company’s lead product candidate, the AdhTAP vaccine enhancer, is designed to restore and augment presentation and subsequent recognition and killing of cancer cells by the immune system. As a stand-alone cancer therapy or in combination with other drugs, AdhTAP could prove to be a key component of a more successful assault on cancer. TapImmune is currently planning the development of AdhTAP for the commencement of clinical manufacturing and toxicology studies.

TapImmune is also developing a TAP-based prophylactic vaccine which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by up to 1,000 times. The company’s TAP technology could also enhance the creation of new vaccines in the fight against many pandemic infectious diseases.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Video Charts http://Videocharts.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please see our Profile for Disclaimers
QualityStocks
Site Admin
 
Posts: 8965
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

yes

Postby rose » Tue Nov 24, 2009 2:09 pm

Where does this one stand in the testing and approvals phase?
I am not a registered investment advisor. Do your own DD
rose
Stock Guru
 
Posts: 985
Joined: Thu Feb 19, 2009 10:25 am
Location: Boston

Postby mwest » Tue Nov 24, 2009 10:56 pm

with the swine flu scare this one is a must
I am not a registered investment advisor and receive payment from DreamTeamGroup for research (view disclaimers: http://dreamteamgroup.com/disclaimer.html).
mwest
 
Posts: 10383
Joined: Thu Apr 09, 2009 3:09 pm

Postby mrsfelix06 » Wed Nov 25, 2009 12:29 pm

yes,and itsn't there still a shortage of vaccines
mrsfelix06
 
Posts: 1055
Joined: Tue Jan 20, 2009 10:00 am

yes

Postby rose » Wed Nov 25, 2009 2:38 pm

If it can gt product to phase III price will jump
I am not a registered investment advisor. Do your own DD
rose
Stock Guru
 
Posts: 985
Joined: Thu Feb 19, 2009 10:25 am
Location: Boston

yes

Postby rose » Fri Nov 27, 2009 3:11 pm

There is so much available money in bio this one could be snatched up
I am not a registered investment advisor. Do your own DD
rose
Stock Guru
 
Posts: 985
Joined: Thu Feb 19, 2009 10:25 am
Location: Boston

Postby QualityStocks » Mon Nov 30, 2009 1:49 pm

TapImmune, Inc. (TPIV.OB) Secures Additional Funding

TapImmune Inc., a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases, announced last week that within the last 60 days the company secured an additional $600,000 in equity funding, bringing the total for the last six months of 2009 to over $1,000,000. The recent investors acquired $.80 units with each unit comprised of one share and one warrant exercisable at $1.20 for a period of 5 years.

The recent restructuring taken place at TapImmune has provided a more secure framework from which to pursue investment and industry partnerships. The company is dedicated to working diligently to secure additional funding and to move its product development and business forward.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Video Charts http://Videocharts.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please see our Profile for Disclaimers
QualityStocks
Site Admin
 
Posts: 8965
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

yes

Postby rose » Mon Nov 30, 2009 2:24 pm

This is a steal
I am not a registered investment advisor. Do your own DD
rose
Stock Guru
 
Posts: 985
Joined: Thu Feb 19, 2009 10:25 am
Location: Boston

Postby mwest » Mon Nov 30, 2009 10:29 pm

Lot's of potential on this one
I am not a registered investment advisor and receive payment from DreamTeamGroup for research (view disclaimers: http://dreamteamgroup.com/disclaimer.html).
mwest
 
Posts: 10383
Joined: Thu Apr 09, 2009 3:09 pm

Postby mrsfelix06 » Tue Dec 01, 2009 9:55 am

Thats a good amount of money
mrsfelix06
 
Posts: 1055
Joined: Tue Jan 20, 2009 10:00 am

yes

Postby rose » Tue Dec 01, 2009 2:48 pm

$1.20 warrents oh my who did that deal WB?
I am not a registered investment advisor. Do your own DD
rose
Stock Guru
 
Posts: 985
Joined: Thu Feb 19, 2009 10:25 am
Location: Boston

yes

Postby rose » Wed Dec 02, 2009 2:22 pm

Ready to play
I am not a registered investment advisor. Do your own DD
rose
Stock Guru
 
Posts: 985
Joined: Thu Feb 19, 2009 10:25 am
Location: Boston

yes

Postby rose » Thu Dec 03, 2009 2:58 pm

Please post phase approval time-line
I am not a registered investment advisor. Do your own DD
rose
Stock Guru
 
Posts: 985
Joined: Thu Feb 19, 2009 10:25 am
Location: Boston

Postby QualityStocks » Fri Dec 04, 2009 10:10 am

TapImmune, Inc. (TPIV.OB) Signs License Agreement with Crucell (CRXL)

TapImmune Inc., best known for developing immunotherapeutic vaccines for cancer and infectious diseases, announced recently that it has signed a license agreement with Crucell N.V. (NASDAQ: CRXL), a global biopharmaceutical company based in the Netherlands. The license allows TapImmune to use Crucell’s proprietary PER.C6® cells in its development programs.

The cell line is ideal for the development and large-scale production of a wide variety of biopharmaceuticals. Specifically, PER.C6 cells do not generate replication competent adenoviruses in the use of recombinant vaccines using adenoviral vectors, making it excellent for the production of adenoviral vectors for clinical applications. Generally, the PER.C6 cell line is the best documented line for vaccine development to date. Its extensive Biologics Master File at the U.S. FDA can be cross-referenced by licensees, resulting in simplification and acceleration of the IND filing and approval process.

The agreement is important for the production of TapImmune’s vaccine products. TapImmune’s primary product candidate, the AdhTAP vaccine enhancer, is designed to help the body’s immune system identify cancer cells so that it can destroy them. It does this by restoring and augmenting antigen presentation and subsequent recognition and killing of cancer cells by the immune system. TapImmune is currently planning for the commencement of clinical manufacturing and toxicology studies.

TapImmune is also developing a TAP based prophylactic vaccine, which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by as much as 1,000 times. As a vaccine, TAP technology could be significant in the fight against many pandemic infectious diseases. As a cancer therapy, TAP vaccine could prove to be a key component in a more successful assault on cancer.

The partnership between TapImmune and Crucell also gives Crucell the right to negotiate a license for TapImmune’s TAP technologies for infectious disease indications.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Video Charts http://Videocharts.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please see our Profile for Disclaimers
QualityStocks
Site Admin
 
Posts: 8965
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Postby mwest » Fri Dec 04, 2009 11:24 pm

a product for a great use, it's about time
I am not a registered investment advisor and receive payment from DreamTeamGroup for research (view disclaimers: http://dreamteamgroup.com/disclaimer.html).
mwest
 
Posts: 10383
Joined: Thu Apr 09, 2009 3:09 pm

Postby mrsfelix06 » Mon Dec 07, 2009 10:47 am

good point mwest
mrsfelix06
 
Posts: 1055
Joined: Tue Jan 20, 2009 10:00 am

yes

Postby rose12 » Mon Dec 07, 2009 3:02 pm

Good move for diversification and will make the co. more viable as a take over target
I am not a registerd investment advisor do DD
rose12
 
Posts: 680
Joined: Mon Dec 07, 2009 2:57 pm

Postby mwest » Mon Dec 07, 2009 10:26 pm

helping to cure cancer this is awesome
I am not a registered investment advisor and receive payment from DreamTeamGroup for research (view disclaimers: http://dreamteamgroup.com/disclaimer.html).
mwest
 
Posts: 10383
Joined: Thu Apr 09, 2009 3:09 pm

Next

Return to QualityStocks Previous Clients

Who is online

Users browsing this forum: No registered users and 1 guest